These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38151388)

  • 1. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.
    Phillips T; Lugtenburg P; Kalsekar A; Mutebi A; Wang A; Blaedel J; Kosa K; Martin S; Sacchi M; Kilavuz N; Thieblemont C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e78-e87.e2. PubMed ID: 38151388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
    Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
    Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
    Shah J; Shacham S; Kauffman M; Daniele P; Tomaras D; Tremblay G; Casasnovas RO; Maerevoet M; Zijlstra J; Follows G; P Vermaat JS; Kalakonda N; Goy AH; Choquet S; Den Neste EV; Hill BT; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos TP; Samal P; Nagy A; Ku M; Canales Albendea MÁ
    Future Oncol; 2021 Apr; 17(11):1295-1310. PubMed ID: 33528286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.
    Herdman M; Kerr C; Pavesi M; Garside J; Lloyd A; Cubi-Molla P; Devlin N
    J Patient Rep Outcomes; 2020 Mar; 4(1):22. PubMed ID: 32219576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Spira A; Zhou X; Chen L; Gnanasakthy A; Wang L; Ungar D; Curiel R; Liao L; Radford J; Kahl B
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):158-168. PubMed ID: 34690090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
    Thieblemont C; Karimi YH; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Jurczak W; Do YR; Gasiorowski R; Lewis DJ; Kim TM; van der Poel M; Poon ML; Feldman T; Linton KM; Sureda A; Hutchings M; Dinh MH; Kilavuz N; Soong D; Mark T; Sacchi M; Phillips T; Lugtenburg PJ
    Leukemia; 2024 Dec; 38(12):2653-2662. PubMed ID: 39322711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
    Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
    Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
    Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
    Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
    Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
    Takaura K; Ando H; Ganoza ER
    Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy.
    Balitsky A; Pond GR; Davies GA; Fraser G; Kouroukis T; Levine M; Meyer RM; Foley R
    BMC Cancer; 2024 Aug; 24(1):984. PubMed ID: 39123197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
    Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
    Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
    Hess G; Rule S; Jurczak W; Jerkeman M; Santucci Silva R; Rusconi C; Caballero D; Joao C; Witzens-Harig M; Bence-Bruckler I; Cho SG; Zhou W; Goldberg JD; Trambitas C; Enny C; Vermeulen J; Traina S; Chiou CF; Diels J; Dreyling M
    Leuk Lymphoma; 2017 Dec; 58(12):2824-2832. PubMed ID: 28556689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.
    Criscitiello C; Spurden D; Piercy J; Rider A; Williams R; Mitra D; Wild R; Corsaro M; Kurosky SK; Law EH
    Clin Ther; 2021 Jul; 43(7):1228-1244.e4. PubMed ID: 34256965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.